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The canonical TGF-b/Smad signaling pathway was delineated in the mid 90s and enriched over the
past decade with many ﬁndings about its speciﬁcity, regulation, networking, and malfunctions in
disease. However, a growing understanding of the chromatin status of a critical class of TGF-b target
genes – the genes controlling differentiation of embryonic stem cells – recently prompted a reexam-
ination of this pathway and its critical role in the regulation of stem cell differentiation. The new
ﬁndings reveal master regulators of the pluripotent state set the stage for Smad-mediated activation
of master regulators of the next differentiation stage. Furthermore, a novel branch of the TGF-b/
Smad pathway has been identiﬁed in which a chromatin-reading Smad complex makes the master
differentiation genes accessible to canonical Smad complexes for transcriptional activation. These
ﬁndings provide exciting new insights into the global role of TGF-b signaling in the regulators of
stem cell fate.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. The canonical model and its regulation
The transforming growth factor b (TGF-b family plays central
roles in the development and maintenance of metazoan organisms
[11,19,30,44,54]. This large family of paracrine factors regulates
functions that guide the exit of embryonic stem cells from the plu-
ripotent state, and the subsequent differentiation of committed
progenitors to more restricted cell fates for the establishment of
body axes, mature tissues, and whole organs. In most cell types,
TGF-b signaling additionally controls the expression of a plethora
of homeostatic genes whose activity determines cell proliferation,
extracellular matrix production, paracrine factor secretion, cell–
cell contacts, immune function, and tissue repair. Pathway feed-
back and crosstalk responses are also built into the transcriptional
program of TGF-b in most cell types.
Regulation of gene expression is central to all these effects. The
TGF-b signal transduction pathway is largely a pathway for tran-
scriptional control. TGF-b factors initiate signaling by binding to
a multi-component receptor complex that includes two pairs
(types I and II) of receptor serine/threonine kinases. The type II
receptor subunits in this complex phosphorylate and activate the
type I receptors, which then phosphorylate and activate Smad
transcription factors to propagate the signal. The TGF-b, nodal, acti-chemical Societies. Published by E
Genetics Program, Box 116,
venue, New York, NY 10065
ue@ski.mskcc.org (J. Massa-vin and myostatin members of the family bind to receptors that
phoshorylate Smad2 and Smad3, and in some cases Smad1. Bone
morphogenetic protein (BMP) receptor phosphorylate Smads 1, 5
and 8. A common fate of these receptor-regulated Smads (RSmads)
is to form complexes with Smad4, which binds tightly to the recep-
tor-phosphorylated C-terminal tail of RSmads. Ancillary Smad-
independent pathways are activated by TGF-b in a context depen-
dent manner through interactions with the receptors that remain
under investigation [31].
In the basal state Smads cycle constantly between the cyto-
plasm and the nucleus, but once activated by receptor action, the
resulting RSmad–Smad4 complexes accumulate in the nucleus
and bind to speciﬁc promoter elements throughout the genome.
The N-terminal globular domain of Smad proteins contains a
DNA-binding ﬁnger that preferentially recognizes the sequence
CAGAC, known as Smad Binding Element (SBE). To achieve high
afﬁnity and speciﬁcity for target sequences, Smad4-RSmad com-
plexes recruit additional DNA-binding proteins into the complex.
The ﬁrst such cofactor to be identiﬁed was the forkhead-box family
member FoxH1 (previously known as Fast1). The Foxh1–Smad2/3–
Smad4 complex binds to a composite site known as the ‘‘activin re-
sponse element’’ (ARE) on target differentiation genes in embryo
cells [45]. Other factors belonging to different families of DNA-
binding proteins have since been identiﬁed that, in a similar
manner, cooperate with Smad complexes in binding to speciﬁc
promoter sequences. Each of the resulting complexes targets a par-
ticular subset of TGF-b responsive genes, called a ‘‘synexpression
group’’, for coordinated regulation of cellular activities [32].lsevier B.V. All rights reserved.
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such as p300, CBP, P/CAF, and GCN5 [21,22,33], Mediator, which is
a multi-subunit co-activator complex that bridges with the C-ter-
minal domain of RNA polymerase (Pol) II [24], and the SWI/SNF
chromatin remodeling complex that repositions nucleosomes to
facilitate transcription [41,55]. These interactions stimulate the
transcriptional output of the target genes. Alternatively, depending
on the promoter context, the Smad complex may recruit histone
deacetylases such as HDAC4 for transcriptional inhibition [23].
The end result of these ﬁndings is a model for signal-driven regu-
lation of gene expression that reconciles the biochemical simplicity
of the TGF-b receptor/Smad signal transduction process with the
broad diversity and context-dependence of its transcriptional tar-
gets and cellular responses [33].
Many modulators of this process have been identiﬁed that con-
trol the receptor access and activity of Smad proteins
[13,20,28,47,51,59], their movements in and out of the nucleus
[57,58,60], their cooperation with other signal-activated transcrip-
tion factors [2,33,52], their interactions with transcriptional cofac-
tors [33], the recycling of activated Smads by dephosphorylation
[7] and poly(ADP)-ribosylation [29], or their removal by polyubiqu-
inylation and proteasome-dependent degradation [2,12,14,15,43].
2. Chromatin status of TGF-b target genes
This long-standing model of the TGF-b/Smad pathway is ade-
quate to explain how TGF-b factors regulate genes that control cel-
lular homeostasis (Fig. 1A). External signals like those conveyed by
the Smad pathway control cell behavior by modulating up or down
the basal activity of such genes. These genes are in an active state
within the euchromatin, and their Smad binding sites are likely
well exposed to incoming Smad4–RSmad complexes. The net effect
of TGF-b- or BMP-activated Smads is to increase or decrease Pol II
action and the transcriptional output of these genes, typically
within a 5-fold range.A. Active target genes
B. Poised target genes
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Fig. 1. Model of nodal regulation of gene expression in embryonic stem cells. (A) Activ
feedback (e.g. SerpinE1 and Smad7, respectively) are in a transcriptionally active state w
associated with DNA-binding cofactors (‘‘xyz’’), readily bind to these sites for stimula
differentiation (e.g. Gsc and Mixl1) have Smad binding sites secluded by repressive chrom
recruits SetDB1 to differentiation genes. SetDB1 catalyzes Lys9 trimethylation on hist
repression. When H3K9me3 is accompanied with unmodiﬁed K4 and acetylated K18 (H
nodal signals. The TRIM33–Smad2/3 complex binds to H3K4–K9me3–K18ac, displacing
sites. Foxh1 is a Smad cofactor for speciﬁc recognition of these sites. Thus, Gsc and Mixl
through the joint action of a TRIM33–Smad2/3 chromatin-binding complex and a SmadThis general model also applies to TGF-b gene responses that
control cell fate. However, recent evidence coming from the ﬁeld
of transcriptional regulation in stem cell differentiation raised
questions about the ability of this model to adequately explain
the regulation of differentiation genes by TGF-b signals. In contrast
to the accessible state of homeostasis modulator genes, the genes
that encode master regulators of stem cell differentiation are
guarded by chromatin structures that bar access to transcriptional
activators (Fig. 1B). This level of protection makes sense because
the activation of such genes irrevocably commits stem cells to dif-
ferentiated lineages and end the pluripotent state. However, while
master differentiation genes are kept in a repressed state, they are
also ready for activation by appropriate signals. These genes may
harbor RNA polymerase II (Pol II) at the transcription start site,
paused but ready to proceed with transcription elongation under
the right command [63]. Therefore, master differentiation genes
and their chromatin are said to be in a ‘‘poised state’’, that is, a state
that is repressed yet set for activation.
The biochemical basis for the poised state of master differentia-
tion genes in embryonic stem cells (ESCs) includes certain chroma-
tinmodiﬁcations. Oct4, Sox2 andNanog,which are core enforcers of
the pluripotent state, are also responsible for some of these modiﬁ-
cations [63]. These proteins form a DNA-binding complex that in
turn stimulates chromatin-modifying factors including polycomb
group (PcG) proteins, SetDB1, and others. PcG complexes mediate
methylation of histone H3 at Lys27, which is a repressive mark,
whereas SetDB1 catalyzes trimethylation of Lys9 on histone H3
(H3K9me3) (Fig. 1B). H3K9me3 is a hallmark of heterochromatin
[34] and serves as a docking site for heterochromatin protein 1
(HP1). HP1 bound to H3K9me3 is thought to form dimers that strap
nucleosomes together for compaction of the chromatin, leading to
gene repression [42]. However, H3K9me3 and HP1 are also present
in ‘‘heterochromatinic’’ regions of the euchromatin [46]. SetDB1 un-
der the command of Oct4, Sox2 and Nanog may create such regions
around master differentiation genes.xyz
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3K4–K9me3–K18ac motif), it provides a platform for activation of Gsc and Mixl1 by
HP1 to relax the chromatin and provide Smad4–Smad2/3 with access to its binding
1 in ESCs are in a ‘‘poised’’ state that is silent but ready for nodal-driven activation
4–Smad2/3 Pol II activating complex.
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The nature of the poised state implies that activation of ESC dif-
ferentiation genes by the TGF-b/SMAD pathway has restrictions
that may not apply to the regulation of readily accessible homeo-
stasis genes. This knowledge posed a conundrum: if master regula-
tor genes are secluded from access by promoter-binding
transcription factors like Smads, how do Smads gain access to
these genes?
An early encounter with this situation occurs when the TGF-b
family member nodal activates master regulators of mesendoder-
mal differentiation during mouse embryogenesis. Nodal is highly
expressed in the node, which is the organizer of gastrulation and
differentiation of the three germ layers – ectoderm, mesoderm
and endoderm – in vertebrates. In the absence of nodal, embryo-
genesis is halted right after gastrulation. In the mouse, nodal is also
essential for the organization of left-right axial structures, neural
patterning, and other developmental events.
Nodal induces mesendodermal differentiation in ESCs by induc-
ing the expression of goosecoid (Gsc), Mix-like homeodomain protein
1 (Mixl1), and other master differentiation genes [6,8,16]. Gsc is a
member of the bicoid subfamily of paired homeobox transcription
factors, and Mixl1 of the Mix/Bix subfamily. Gsc and Mixl1 are ex-
pressed in the primitive streak to mediate gastrulation, axial mes-
endoderm morphogenesis, and endoderm formation. Nodal
activates Gsc andMixl1 expression through nodal/activin receptors,
including the type I receptors ALK4 and ALK7, and the type II
receptors ActR-II and ActR-IIB [40,62]. The receptors phosphorylate
Smads 2 and 3, leading to the formation of a Smad2/3–Smad4–
Foxh1 complex (Fig. 1B). This complex binds to AREs in the proxi-
mal promoters of Gsc and Mixl1 for transcription activation [8,26].
In ESCs however Gsc and MixL1 are in the poised, repressed state.
Therefore, something must happen ﬁrst in order for Smad2/3–
Smad4–Foxh1 to gain access to these AREs.
4. TRIM33 enters the scene
A recent investigation of how Smad complexes gain access to
the AREs in Gsc and Mixl1 turned the focus to TRIM33 (Tripartite
Motif protein 33) [17,38]. The TRIM family of proteins includes
more than seventy members that are deﬁned by a motif of contig-
uous RING-ﬁnger, B-box, and coiled-coil domains in the N-terminal
region of the proteins. The RING domain of many TRIM proteins
has E3 ubiquitin ligase activity that can mediate ubiquitylation of
the TRIM protein itself and of other proteins. The coiled-coil do-
main mediates protein TRIM protein homo- and hetero-oligomeri-
zation. TRIM family members are involved in a broad range of
biological processes, in many cases through the control of gene
expression. A prominent member of this family, PML (TRIM19), is
involved in the t(15;17) translocation of acute promyelocytic
leukemia.
TRIM33 (also known as transcription intermediate factor 1c,
TIF1c), TRIM24 (TIF1a), TRIM28 (TIF1b, KAP1), and TRIM66 (TIF1d),
form a subfamily that is characterized by the presence of a PHD do-
main and a Bromodomain (Bromo) in the C-terminal region of the
proteins. TRIM24 binds estrogen receptors to activate estrogen-
dependent genes associated with cellular proliferation and tumor
development [50], and retinoic acid receptor-a (RARa) to attenuate
RARa-mediated transcription [27]. TRIM28 is implicated in gene
silencing as a component of the NCoR1 nuclear receptor repressor
complex and the NuRD nucleosome-remodeling complex [17,38].
TRIM66 expression is restricted to the testis [25].
The entry of TRIM33 into the TGF-b scene was smooth at ﬁrst
but soon turned confusing. Several studies suggested that TRIM33
is a negative regulator of Smad4 and a general inhibitor of TGF-bfamily signaling [1,9,10,35]. Knockdown of TRIM33 in Xenopus
embryos enhanced mesendoderm induction [10]. TRIM33 knock-
down in mouse resulted in excessive nodal signaling [35]. In cell-
based assays using promoter constructs driving reporter genes,
TRIM33 scored as an inhibitor of TGF-b dependent transcription
[1,10,18]. These observations and the presence of a RING-ﬁnger do-
main in TRIM33 ﬁt with the notion that TRIM33 might be an inhib-
itor of Smad4 in TGF-b and BMP pathways. Indeed, in vitro and in
overexpressing cells TRIM33 can mediate poly-ubiquitylation and
degradation of Smad4 [10], although this was later revised to
TRIM33 mediating inhibitory mono-ubiquitylation of Smad4 in a
histone-dependent manner [1,9].
TRIM33-deﬁcient mouse embryos lack mesoderm, and this was
hard to explain in the face of seemingly high levels of nodal signal-
ing [35]. The notion that TRIM33 is an inhibitor of Smad4 function
had been challenged by the ﬁnding that TRIM33 binds to Smad3,
and it does so with higher afﬁnity than for Smad4 [18]. Upon
TGF-b stimulation, the pool of phosphorylated Smad3 is distrib-
uted between separate TRIM33–Smad2/3 and Smad4–Smad2/3
complexes. Knockdown of TRIM33 had little or no effect on classi-
cal TGF-b target genes controlling cell homeostasis. In human
hematopoietic progenitor cells TRIM33 was dispensable for TGF-
b mediated cell cycle arrest (a homeostatic response that is driven
by Smad2/3–Smad4). Notably, TRIM33 was required in these cells
for TGF-b stimulation of erythroid differentiation. Based on these
observations, it was proposed that the TGF-b-activated Smad path-
way has two arms, a canonical Smad4–Smad2/3 arm that mediates
homeostatic gene responses and a TRIM33–Smad2/3 arm that, in
hematopoietic progenitors at least, stimulates differentiation
[18]. This resonated with evidence that in zebraﬁsh TRIM33 is re-
quired for erythropoiesis [39] and it acts as a transcriptional elon-
gation of erythroid differentiation genes [4]. Furthermore, the
conditional knockout of TRIM33 in premalignant pancreatic pro-
genitors phenocopies the effect of Smad4 conditional knockout,
suggesting that TRIM33 and Smad4 converge on pancreatic tumor
suppression [5,53]. However, without hard evidence for a direct
involvement of TRIM33 in TGF-b-dependent gene regulation, the
controversy about the role of TRIM33 in Smad signaling went on.
5. TRIM33 as a direct TGF-b signal transducer
Hard evidence for a role of TRIM33 as a signal transducer and
direct mediator of transcription in the TGF-b pathway was recently
provided by studies in ESCs. A combination of genetic, biochemical
and structural evidence demonstrated an essential role for TRIM33
in nodal activation of Gsc andMixl1 during ESC differentiation [56].
TRIM33 is present in the majority of nuclei in all regions of the
gastrulating embryo, including the node and primitive streak
[56]. In mouse ESCs derived from the inner cell mass, ligand activa-
tion of nodal/activin receptors rapidly induces the formation of
biochemically separate TRIM33–Smad2/3 and Smad4–Smad2/3
protein complexes (Figs. 1B and 2). Under conditions that allow
differentiation, ESCs form structures known as embryoid bodies
(EBs) that in response to external factors differentiate into all three
germ layer fates [37]. Notably, TRIM33-deﬁcient mouse and hu-
man ESCs form EBs that undergo ectoderm differentiation but fail
to undergo mesendodermal differentiation in response to auto-
crine nodal [56]. Stimulation of nodal/activin receptors by added li-
gand in EBs acutely activates the expression of mesendodermal
differentiation genes such as Gsc, Mixl1 and others, together with
stimulation of homeostasis genes such as SerpinE1, Skil and Smad7
(Fig. 2). Whereas Smad2/3 and Smad4 are required for the vast
majority of these gene responses, TRIM33 was required for the dif-
ferentiation gene responses but not the homeostatic responses.
Genome-wide transcriptomic analysis showed that a large propor-
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Fig. 2. Complementary branches of the TGF-b/Smad pathway in embryonic stem
cells. TGF-b signaling involves the binding of ligand to two pairs of receptor serine/
threonine kinases for the assembly of a receptor complex that phosphorylates
RSmad proteins (Smads2 and 3 in the case of TGF-b and nodal receptors). The
receptor-phosphorylated RSmads bind to Smad4, assembling complexes that
recognize speciﬁc promoter elements to stimulate or inhibit transcription. In a
newfound second branch of this pathway, receptor-phosphorylated Smad2/3 bind
to TRIM33, assembling complexes that recognize certain repressive marks on the
chromatin. The Smad4–Smad2/3 complex is necessary and sufﬁcient for TGF-b
regulation of cell homeostasis genes that are in an active state. However, master
differentiation genes in ESCs are secluded by repressive chromatin marks. Activa-
tion of these genes by TGF-b signals requires TRIM33–Smad2/3 in addition to the
Smad4–Smad2/3. Smad4-independent gene responses may also exist.
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TRIM33. In contrast, almost all TGF-b responses in human kerati-
nocyte and breast carcinoma cell lines are homeostatic and require
Smad2/3 and Smad4 but not TRIM33.
The PHD-Bromo cassette of TRIM33 is essential for its function
as a Smad signal co-transducer in the nodal TGF-b pathway [56]. In
contrast, mutation of the RING ﬁnger domain did not inhibit the
transcriptional activity of TRIM33. The PHD and Bromo domains
typically bind to post-translationally modiﬁed histones [48,61].
Analysis of the histone binding ability of the TRIM33 PHD-Bromo
cassette revealed a high afﬁnity for histone H3 containing unmod-
iﬁed K4, K9me3 and K18ac. Notably, the mark of poised master
regulators, H3K9me3, is critical for the TRIM33-histone H3
interaction.
The X-ray crystal structure of the PHD-Bromo cassette bound to
its cognate histone H3 modiﬁcations provided key insights into the
mechanism of action of TRIM33. The structure shows that the
TRIM33 PHD binds to unmodiﬁed K4 and K9me3 whereas Bromo
binds the K18ac mark on the same H3 tail [56]. The structure also
explains why methylation of K4 disrupts recognition by TRIM33.
The speciﬁcity of the TRIM33-histone interaction is noteworthy.
Whereas the TRIM24 Bromo recognizes the H3K23ac mark [50],
the TRIM33 Bromo recognizes H3K18ac, as determined by the
anchoring interaction of the PHD with K9me3 [56]. The spacer
length between the methylation and acetylation marks on histone
H3, as well as the sequence context of these marks, are key deter-minants of molecular recognition by the TRIM33 PHD/Bromo cas-
sette. A recent proposal that TRIM33 binds to K18ac and K23ac
acetylation marks on the same histone H3 tail [1], is not tenable
based on the crystal structure. Thus, the combination of unmodi-
ﬁed K4, K9me3 and K18ac marks on histone H3 tails constitutes
a unique recognition code for the binding of TRIM33. The com-
bined binding speciﬁcity for modiﬁed histone and DNA mediated
by TRIM33 and Smad2/3, respectively, ensures further selectivity
in target gene recognition.
6. A dance of complexes
The Gsc andMixl1 promoters in ESCs contain key features of the
poised state, including the H3K9me3 mark of quiescent chromatin,
the chromatin compacting factor HP1c bound to this mark, and a
basal level of RNA Pol II loaded on the start site [56] (Fig. 1B).
The recent evidence suggests that nodal TGF-b signals activate
these master mesendoderm regulator genes by means of two coop-
erative Smad complexes in four steps. On binding ligand, the nodal
receptors phosphorylate Smad2/3 leading to the generation of
TRIM33–Smad2/3 and Smad4–Smad2/3 complexes. Next,
TRIM33–Smad2/3 binds to nucleosomes containing histone H3
with K4–K9me3–K18ac in the Gsc and Mixl1 promoters. The supe-
rior afﬁnity of TRIM33 for H3K9me3–K18ac displaces bound HP1c
form these nucleosomes. This requires Smad2/3 and nodal input,
suggesting the action of the complex depends on TRIM33 binding
to H3K9me3-K18ac and Smad2/3 binding to an adjacent SBE. Third,
through as yet unknown mechanisms, but possibly just by evicting
HP1, the TRIM33–Smad2/3 complex regionally remodels the chro-
matin to expose the AREs. Then, and only then, can the Smad4–
Smad2/3–Foxh1 complex bind to the AREs for stimulation of Pol
II dependent transcription of Gsc and Mixl1[56]. TRIM33-indepen-
dent homeostatic gene responses (Smad7, SerpinE1 and others) go
on in parallel (Fig. 1). Smad4–Smad2/3 access to these gene pro-
moters may solely depend on the availability of speciﬁc DNA-bind-
ing Smad partners, following the classical principles of the
canonical TGF-b pathway as previously known [33].
The end result of these events is that nodal switches Gsc and
Mixl1 from the poised state to the activated state, triggering mes-
endodermal differentiation. In this context, the observed ability
of TRIM33 to mediate Smad4 ubiquitylation [1,10] might provide
a negative feedback activity for the inactivation of Smad4 and sig-
nal turnover, a point that is open to investigation. As precedent, the
Pol II kinases CDK8 and CDK9 phosphorylate Smads1–3 for full
activation but, in the process, these phosphorylations prime Smads
for ubiquitylation and degradation [2,3]. Smad4 inactivation by
poly-(ADP)-ribosyltation provides another mechanism for decom-
missioning Smad4 in transcriptional complexes [29].
These insights also suggest a biochemical deﬁnition of the
poised state of master regulator genes: the H3K9me3 mark pro-
vides a binding site for HP1 proteins that impose gene repression
but, at the same time, H3K9me3 provides an entry point for
TRIM33 to displace HP1 and allow signal-driven gene expression.
The external TGF-b signals therefore use a repressive chromatin
mark as a platform for activation of master regulators of
differentiation.7. Master programs of TGF-b responsiveness
The work reviewed above has shown that master enforcers of
the pluripotent state implement chromatin modiﬁcation that serve
to poise master regulators of the next stage, such as Gsc and Mixl1,
for activation by nodal signaling. In a remarkable convergence of
complementary ﬁndings, recent studies on genome-wide binding
patterns of lineage-speciﬁc transcription factors have provided a
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speciﬁc responsiveness to TGF-b signals [36,49]. Using chromatin
immunoprecipitation coupled with massive parallel sequence
analysis (ChIP-seq), it was shown that nodal-activated Smad3 in
ESC co-occupies the genome with Oct4. These observations were
extended to lineage-speciﬁc master enforcers of various commit-
ted progenitor cells, including MyoD1 in myoblasts and PU.1 in
pro-B cells [36]. Furthermore, this paradigm also applies to BMP
signaling and Wnt signaling, whose respective mediators, Smad1
and TCF7L2, in hematopoietic progenitors bind to the genome right
next to master regulators of this lineage [49]. Moreover, Smads can
occupy different cell-speciﬁc enhancers at the same gene in differ-
ent cell lineages as dictated by the stage/lineage-speciﬁc master
regulator. One example of this is provided by Smad3 binding to
Id3, which occurs at an Oct4 targeted enhancer in ESCs and at a
PU.1 targeted enhancer in pre-B cells [36]. These results argue that
cell type-speciﬁc master transcription factors determine what
genes will be competent for binding signal-activated Smads, thus
orchestrating at a global level the lineage-speciﬁc effects of TGF-
b signaling.
At ﬁrst glance these results may seem at odds with the exten-
sive genetic and biochemical evidence that Smad binding is deter-
mined by DNA-binding cofactors that lend added afﬁnity and
selectivity to canonical Smad4-RSmad complexes [33]. A straight-
forward resolution of this apparent conﬂict is suggested by the dif-
ferent nature of two types of Smad3 binding events at gene
promoters. Oct4 imposes chromatin marks such as H3K9me3 that
would determine the pattern of TRIM33–Smad3 binding, as dem-
onstrated in the case of Gsc and Mixl1[56]. Thus, Oct4 (with Sox2
and Nanog) licenses speciﬁc sites for Smad3 binding as part of a
TRIM33–Smad3 complex. This would explain the observed cohab-
itation of Oct4 and Smad3 in common promoter regions through-
out the genome. The Oct4-mediated licensing of speciﬁc
enhancers for Smad3 binding would be necessary but not sufﬁcient
for transcriptional activation of genes. Activation additionally re-
quires binding of the Smad4–Smad2/3–Foxh1 complex. Foxh1 adds
afﬁnity and selectivity for binding the Smad4–Smad2/3–Foxh1
complex to the ARE, which is a composite of Smad binding and
Foxh1 binding elements. AREs, also called Smad/Foxh1 enhancers
(SFEs), are present throughout the genome and deﬁne Smad/Foxh1
gene synexpression groups [45]. The Smad4–Smad2/3–Foxh1 com-
plex would then trigger Pol II transcriptional action. In this model,
Oct4 would direct Smad3 (with TRIM33) to regionally relax the
chromatin and to license these promoters for subsequent binding
of Smad4–Smad2/3–Foxh1 complexes to one set of genes, and
other complexes with other DNA-binding partners to access differ-
ent sets of genes.8. Outlook
Progress in this area over the past few years has brought to a
new level of understanding how TGF-b signals control intersect
with the chromatin of master differentiation genes in stem cells.
The collusion of Smad transcriptional complexes with master reg-
ulator genes and the involvement of a chromatin reader Smad
complexes in gene activation are open doors for a better under-
standing of how stem cell read TGF-b signals.
From the standpoint of TRIM33–Smad2/3 as a mediator of ac-
cess to AREs, it will be important to deﬁne exactly how this com-
plex regionally remodels the chromatin to expose the AREs. Is
this based just on evicting HP1 from H3K9 methylated nucleo-
somes, or is there more to it? TRIM33 has been shown to mediate
transcription elongation of erythroid differentiation genes in
hematopoietic progenitors [4]. The hematopoietic transcription
factor SCL and the elongation factors p-TEFb (including cyclin-T1and CDK9) and FACT participate in this process [4]. Are access to
poised genes and transcription elongation two independent func-
tions of TRIM33, or two sequential functions of the same TRIM33
complex?
Questions also emerge from the role of master enforcers of a
particular developmental stage (e.g. Oct4 and Sox2 in the pluripo-
tent stage) as determinants of Smad3 binding to sites throughout
the genome. For example, does the Oct4-bound Smad3 correspond
to TRIM33–Smad3 complexes or Smad4–Smad3 complexes? And,
how come that thousands of Oct4/Smad3 co-occupied sites are
detected in the genome of ESCs, yet only about 100 of these genes
respond to nodal?
The newly emerging mechanism of TGF-b control of stem cell
differentiation genes may be relevant beyond the TGF-b pathway.
Similar events involving signal-driven chromatin reader complexes
that open the way for signal-driven Pol II activating complexes
may operate in other developmental pathways whose target genes
are also secluded by repressive chromatin. The recent progress
provide a general framework for further analysis of these critical
questions.
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